What is the recommended dose and injection technique of Botulinum toxin (Botox) for treating palmar hyperhidrosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

For palmar hyperhidrosis treatment with Botox (onabotulinumtoxinA), the recommended dosage is typically 50-100 units per palm, as supported by the most recent and highest quality study available 1. The injection technique involves multiple small intradermal injections distributed in a grid-like pattern across the palm, with approximately 1-2 units injected at each site, spaced about 1-1.5 cm apart. Key considerations for the injection technique include:

  • Targeting the entire palmar surface, focusing on areas of maximum sweating
  • Avoiding the thenar and hypothenar eminences to minimize risk of muscle weakness Pain management is essential as palmar injections are uncomfortable; options include:
  • Ice application
  • Topical anesthetics
  • Nerve blocks (median/ulnar)
  • Procedural sedation in sensitive patients The onset of effect typically occurs within 2-7 days, with peak effect at 2 weeks, and results lasting 4-6 months before retreatment is needed, as reported in studies such as 2 and 1. Botox works by blocking the release of acetylcholine from sympathetic nerves that stimulate eccrine sweat glands, thereby reducing sweat production. Potential side effects include:
  • Temporary hand weakness (5-10% of patients)
  • Pain at injection sites
  • Rarely, compensatory hyperhidrosis in untreated areas It is worth noting that while other studies, such as 3 and 4, provide additional information on the treatment of palmar hyperhidrosis, the most recent and highest quality study 1 provides the most relevant guidance for clinical practice. Additionally, a review of management strategies for palmar hyperhidrosis 5 highlights the importance of individualized treatment approaches, taking into account disease severity, benefit-to-risk profile, treatment cost, patient preference, and clinician expertise.

References

Research

Botulinum toxin A for palmar hyperhidrosis.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2001

Research

Botulinum toxin therapy for palmar hyperhidrosis.

Journal of the American Academy of Dermatology, 1998

Research

Management Strategies Of Palmar Hyperhidrosis: Challenges And Solutions.

Clinical, cosmetic and investigational dermatology, 2019

Related Questions

What is the best treatment for palmar hyperhidrosis?
What are the causes and treatment options for palmar hyperhidrosis?
What is the first line of treatment for excessive sweating (hyperhidrosis) in the hands and soles?
What are the treatment options for hyperhidrosis?
What are the treatment options for palmar and plantar hyperhidrosis?
What are the criteria for cervical spine clearance?
What is the best approach for a patient with class III obesity and irregular bowel movements, despite a strict diet and exercise regimen, who is being switched from FiberLax (psyllium) to Metamucil (psyllium)?
What are the current treatment recommendations for conjunctivitis (pink eye)?
What is the best approach to manage a patient with frequent bowel movements (3-5 Bowel Movements (BMs) daily) and obesity (Body Mass Index (BMI) of 40.16), who is currently taking FiberLax (psyllium) and plans to start Metamucil (psyllium), exercises daily, and follows a low-carbohydrate diet, yet is unable to lose weight?
What is the cause of sudden onset bilateral periorbital edema, tender eyelids, and mild headache in a patient taking metformin, atorvastatin, and lisinopril-hydrochlorothiazide, with no history of allergies or recent introduction of new lotions or eyelashes?
What is the cause of sudden onset bilateral periorbital edema (swelling around the eyes) in a patient taking metformin, atorvastatin, and lisinopril-hydrochlorothiazide, with symptoms including tender eyelids and mild headache, but no eye drainage, redness, or itching?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.